Skip to content

Released Oct 29, 2020, before the open

10-Q filed Oct 29, 2020, 29 days after period end · 0001558370-20-011974

Q3 2020 · 10-Q
Revenue$10.79M−24.3% vs Q3 2019−1.6% vs Q2 2020
Net Income-$4.44MN/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.14N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$2,582,000N/M
Operating Cash Flowderived-$3,604,000N/M
Free Cash Flowderived-$3,706,000N/M
Margins · derived
Operating margin-23.9%−13.1 pt vs Q3 2019
Net margin-41.1%−16.1 pt vs Q3 2019

What the release said

The release

Same quarter

MetricQ3 2020Q3 2019Q3 2018Q3 2017
Revenue$10.79M$14.25M$663.00K$7.53M
Net Income-$4.44M-$3.56M-$5.32M-$11.44M
EPS Diluted-$0.14-$0.24-$0.40-$0.09

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR